Category: Mesothelioma
Tips for Helping Mesothelioma Patients Enjoy Fourth of July Celebrations
Today, all Americans celebrate the Fourth of July holiday marking our independence. For many people this means a time of barbecues, family picnics and sun in the fun. Like most holidays though, for mesothelioma patients and their families, it can also be a stressful time with all the added activity.
Here are a few tips to help make the day enjoyable while also taking care of your health:
- Drink plenty of water: The heat can be dehydrating leading to headaches and dizziness. Make sure to sip ice-cold water throughout the day to stay hydrated. Sports drinks are also a great option during the heat of the day.
- Get in the shade or air-conditioning: When your friends and families are outside having fun it can be tough to sneak away to get cool, but it is important to do just that so you do not overheat. Don’t wait until you are miserable from the heat, seek shade or go inside and rest then head back out when you are feeling better.
- Use sunscreen and cover up: If you are undergoing chemotherapy or radiation, you may be more sensitive to the sun. Make sure to cover up with light colored clothing and to use an SPF 30 or higher on your exposed skin.
- Eat small amounts of food: There is sure to be plenty of food at the celebration. Don’t be tempted to overindulge as that can bring on discomfort and GI distress. Eat small amounts of food throughout the day and you will feel much better. Also, be aware that mesothelioma treatments can make you more susceptible to food-borne bacteria. The National Comprehensive Cancer Network (NCCN) recommends that you make sure any food you eat is well-chilled and has not been left out in the heat.
- Take a Dip: You can join in on the fun in the pool. Exercise is recommended for cancer patients, and in the heat there may be nothing more refreshing than a short dip in the pool. According to the NCCN, swimming is a good source of light exercise that will keep you cool, help reduce strain on your joints, and soothe your aching muscles. But, know your limits and rest when needed.
With a little planning the 4th of July can be a fun day and a welcome break from your treatments. Take care of yourself and have a healthy and happy 4th!
Full FDA Approval Granted for Anti-Cancer Drug Targeting EGFR Protein Found in Lung Cancer and Mesothelioma
After continued good news with results in the treatment of lung cancer patients with Tagrisso, an anti-cancer drug, the U.S. Food and Drug Administration announced approval for the drug for lung cancer patients with the EGFR T790M mutation. In April, the European Commission granted full marketing authorization for the drug. Mesothelioma patients around the world stand to benefit from these approvals.
In November 2015, the FDA granted accelerated approval for Tagrisso based on an overall response rate of nearly 60% in 411 patients in clinical trials. Tagrisso is the first and only approved medicine in the US indicated for non-small cell lung cancer patients who have tested positive for the EGFR T790M mutation.
Expert Insight
Sean Bohen, AstraZeneca
“By following the science, we aim to turn lung cancer into a chronic, manageable disease for patients and this milestone brings us one step closer to that ambition.”
The full approval, granted on March 17, was based on the “statistically-significant improvements” for patients in the AURA3 trial with metastatic EGFR T790M mutation-positive NSCLC who had progressive disease following first-line EGFR TKI therapy. In the trial, patients who received Tagrisso achieved a median progression-free survival of 10.1 months compared to 4.4 months in those patients who received a chemotherapy regimen.
“The FDA’s full approval reinforces the potential of Tagrisso to become the standard of care for patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer whose disease has progressed on or after first-generation EGFR-TKI therapy,” said Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, according to a March 31 press release from Astra Zeneca.
EGFR is a protein found on the surface of some cells to which epidermal growth factor binds, which causes the cells to divide and spread. It is found at abnormally high levels on the surface of many types of cancer cells. According to a 2009 article in Current Drug Targets, EGFR overexpression has been shown in more than 50% of pleural mesothelioma patients.
The T790M mutation is the most common resistance mechanism that develops from EGFR TKI therapy, occurring in nearly half of NSCLC patients who have received previous EGFR TKI therapy.
Lung cancer is the leading cause of cancer death in the United States, with an estimated 222,500 new diagnoses and 155,870 deaths in 2017, according to the National Cancer Institute. Pleural mesothelioma is a cancer of the lining of the lungs, with 3,000 new diagnoses each year, and nearly the same number of deaths from the terminal cancer.
To find out if Tagrisso is an option for treating your mesothelioma, talk with your oncologist.
Photo Credit: National Cancer Institute
Sources:
- U.S. Food and Drug Administration
http://www.mercknewsroom.com/news-release/oncology-newsroom/merck-announces-fda-acceptance-review-mk-3475-biologics-license-appli - Astra Zeneca
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/tagrisso-osimertinib-receives-us-fda-full-approval-31032017.html
Mesothelioma Growth Could be Linked to Density of Cancer Cells
As MesotheliomaHelp has reported time and again, the spread of cancer cells, or metastasis, is the biggest challenge for researchers when searching for effective treatments. It is this migration of the cancer cells, according to the National Cancer Society, that is the cause of 90 percent of all cancer deaths. Stopping this spread is critical for improving survival in mesothelioma patients. Now, researchers report they have found the reason cancer cells split off from the primary site, and more importantly, they may also know how to stop the process.
In a May 26 press release from Johns Hopkins, lead researcher Hasini Jayatilaka, a postdoctoral fellow at Johns Hopkins’ Physical Sciences-Oncology Center, found that it is not the overall size of a tumor that leads to metastasis, rather “how tightly those cells are jammed together” that has them break away. Jayatilaka likened the process to waiting for a table in an overcrowded restaurant but then deciding to go elsewhere or moving to the suburbs from the crowded city.
Cancer cells metastasize because they can reproduce quickly and they can get into the bloodstream where they then spread to other organs. When looking deeper into those processes, the team found that when the tumors became “more crowded” the cells secreted proteins that “encouraged migration.” The proteins, Interleukin 6 (IL-6) and Interleukin 8 (IL-8), sent signals basically telling the cancer cells to leave the primary tumor site.
“We found that it was not the overall size of a primary tumor that caused cancer cells to spread, but how tightly those cells are jammed together when they break away from the tumor,” said Jayatilaka. “At a fundamental level, we found that cell density is very important in triggering metastasis.”
When the researchers used two existing drugs at the tumor site, one approved for treating arthritis and the other being tested for breast cancer treatment, the receptors were blocked from receiving those signals, effectively halting the metastasis. Although the growth at the primary tumor site did not stop, the spread of the cancer cells was limited. This helped confirm that by blocking the signaling pathway, they could slow metastasis.
Expert Insight
Dr. Denis Wirtz, Johns Hopkins
“This treatment has the potential to inhibit metastasis and thus improve cancer patient outcomes.”
“In our eight-week experiment, when we used these two drugs together, the growth of the primary tumor itself was not stopped, but the spread of the cancer cells was significantly decreased,” Jayatilaka said. “We discovered a new signaling pathway that, when blocked, could potentially curb cancer’s ability to metastasize.”
Once mesothelioma cells spread to distant regions of the body, the cancer, caused by past asbestos exposure, becomes virtually impossible to eradicate. Getting a handle on the spread of cancer is critical for increasing survival.
“The pharmaceutical companies view metastasis as a by-product of tumor growth,” said Denis Wirtz, Johns Hopkins University’s vice provost for research and director of its Physical Sciences-Oncology Center, and one of the study’s senior authors. “Our study looked more closely at the steps that actually initiate metastasis. By doing this, we were able to develop a unique therapeutic that directly targets metastasis, not the growth of the primary tumor.”
This drug cocktail was tested on mice in the lab, but has not yet been tested on humans. Wirtz said the feedback they have gotten from other researchers has been positive and others see “real potential for this approach.”
Mesothelioma, an asbestos-caused cancer is diagnosed in close to 3,000 Americans each year. There is no cure for the asbestos-caused cancer.
See the full study in the May 26 online issue of Nature Communications.
Sources:
- Nature Communications
http://www.nature.com/ncomms/2016/160524/ncomms11734/full/ncomms11734.html - Johns Hopkins
http://releases.jhu.edu/2017/05/26/new-cellular-target-may-put-the-brakes-on-cancers-ability-to-spread/
Companies Join Forces to Combat Mesothelioma
In November, MesotheliomaHelp reported on the encouraging results with the experimental cancer drug known as CRS-207 in its ongoing Phase 1b trial. Now Aduro Biotech, the maker of CRS-207, is joining forces with Merck, the pharmaceutical company that markets the immunotherapy drug Keytruda (pembrolizumab), to determine whether the combination of the two medications is effective in the treatment of malignant pleural mesothelioma.
Pleural mesothelioma is the signature cancer of asbestos that attacks the linings of the lungs. Although recent breakthroughs in treatment have improved the life expectancy for some patients, the prognosis for patients is poor with survival often less than 18 months. New, effective treatments are critical to bring hope to the mesothelioma community.
According to a May 17 press release from Aduro Biotech announcing the collaboration, based on the results of the company’s Phase 1 mesothelioma trial, and those of other studies that have shown positive results with the combination therapy, the companies are moving forward with the Phase 2 trial.
“Data from our ongoing Phase 1 clinical trial of CRS-207 with standard chemotherapy as frontline treatment for malignant pleural mesothelioma have been very encouraging,” said Natalie Sacks, M.D., chief medical officer at Aduro. “… we look forward to initiating a Phase 2 trial to evaluate the CRS-207/pembrolizumab combination in patients with malignant pleural mesothelioma who have failed prior treatment.”
The Phase 2 trial is currently recruiting patients with a goal to enroll 35 mesothelioma patients whose cancer has continued to progress despite undergoing one or two prior anti-cancer therapies. The trial, that has an estimated completion date of March 2019, is an extension of a collaboration between the two companies testing the same combination of drugs in gastric cancers.
According to Aduro Biotech, CRS-207 is a Listeria-based vaccine that has been engineered to stimulate an immune response to mesothelin, which is over-expressed in many cancers, including mesothelioma. According to one study, more than half of the mesothelioma patients at diagnosis had significantly elevated levels of mesothelin in their blood.
Keytruda, an immunotherapy drug from Merck that awakens the immune system to effectively fight off cancer cells, has been approved in the U.S. for use in melanoma and lung cancer patients after a prior round of chemotherapy failed to stop progression of the disease. Keytruda works by targeting the cellular pathway known as PD-1/PD-L1 (proteins found on the body’s immune cells and some cancer cells). Most recently, the U.S. Food and Drug Administration has granted accelerated approval to Keytruda as a treatment based solely on the genetic mutations of a cancer and not on the type of cancer.
The CRS-207/pembrolizumab mesothelioma trial will take place at various centers across the U.S. Currently, the Moffitt Cancer Center in Tampa, FL and University of Chicago Medical Center are recruiting patients. Mesothelioma patients should talk to their oncologist to determine if this trial might be right for them.
To find out more about the collaborative trial using CRS-207 and Keytruda see ClinicalTrials.gov.
https://clinicaltrials.gov/ct2/results?term=%22malignant+mesothelioma%22&recr=Open&pg=1
Sources:
- Aduro Biotech
http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2273583 - U.S. Food and Drug Administration
http://www.mercknewsroom.com/news-release/oncology-newsroom/merck-announces-fda-acceptance-review-mk-3475-biologics-license-appli
First-Ever FDA Approval of Anti-Cancer Drug Based on Biomarker and Not Cancer Type Is Encouraging for Mesothelioma Patients
Last week MesotheliomaHelp reported on the drive towards using DNA sequencing on cancer patients in an effort to determine the appropriate treatment based on the patients’ biomarkers. Keytruda, that targets the PD-L1 marker, was cited as an example in that article. Now, the U.S. Food and Drug Administration has granted accelerated approval to Keytruda as a treatment based solely on the genetic mutations of a cancer and not on the type of cancer.
The FDA announced in a May 23 press release, that this is the first-ever approval of a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Keytruda has already been approved for in the U.S. for use in melanoma and lung cancer patients after a prior round of chemotherapy failed to stop progression of the disease. This approval is for unresectable or metastatic solid tumors, of any type, that have been identified as having a biomarker referred to as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
Expert Insight
Richard Pazdur, M.D., FDA
“This is an important first for the cancer community.”
“Until now, the FDA has approved cancer treatments based on where in the body the cancer started—for example, lung or breast cancers,” said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research and director of the FDA’s Oncology Center of Excellence. “We have now approved a drug based on a tumor’s biomarker without regard to the tumor’s original location.”
This approval, according to the FDA, was based on the results of five clinical trials for patients with MSI-H or dMMR solid tumors. The patients had a variety of cancers, including colorectal and endometrial. Of the 149 patients who received Keytruda in the trials, nearly 40 percent had a complete or partial response, with 78 percent of those patients seeing a lasting response for six months or longer.
“The FDA’s approval of this first-of-its-kind, tumor-agnostic, indication is further evidence of Merck’s commitment to helping people with difficult-to-treat cancers, and to advancing the use of biomarkers to guide clinical decision-making,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories, in a May 25 press release announcing the approval.
This approval has far-reaching implications for the mesothelioma community for future approvals of biomarker-driven drugs. Significant research has been conducted to find those biomarkers that drive the uncontrollable growth of mesothelioma, and other cancers, and this landmark approval moves oncologists much closer to offering personalized care. Targeted therapy improves quality of life and increases survival for cancer patients.
“This approval for Keytruda is a transformational milestone in our progress toward personalized immunotherapy, offering certain patients with difficult-to-treat cancers a medicine based on the genetic makeup of the tumor – regardless of tumor type,” said Dr. Luis A. Diaz, Jr., head of the Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center.
Mesothelioma is an asbestos-caused cancer with a prognosis often less than 18-months. New, effective treatment options are critically important to allow patients to live longer lives.
Patients should talk to their oncologists to determine whether Keytruda is a treatment option for them. Visit the Keytruda website to find out more about the drug.
Sources:
- FDA
https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.htm - Merck Research Laboratories
http://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-keytruda-pembrolizumab-adult-and-pediatr - Keytruda website
https://www.keytruda.com/?cc=F56EF8DC&csid=General_Brand_Lung&gclid=CjwKEAjw4IjKBRDr6p752cCUm3kSJAC-eqRtAmMqxwdRx6gjIkSciP4aQ8fZl3M5fzF-2jLSDG5kmhoCzVbw_wcB
Free Mesothelioma Patient & Treatment Guide
We’d like to offer you our in-depth guide, “A Patient’s Guide to Mesothelioma,” absolutely free of charge.
It contains a wealth of information and resources to help you better understand the condition, choose (and afford) appropriate treatment, and exercise your legal right to compensation.
Download Now